AU2021213469B2 - Compositions for the treatment of angiolipoma - Google Patents

Compositions for the treatment of angiolipoma

Info

Publication number
AU2021213469B2
AU2021213469B2 AU2021213469A AU2021213469A AU2021213469B2 AU 2021213469 B2 AU2021213469 B2 AU 2021213469B2 AU 2021213469 A AU2021213469 A AU 2021213469A AU 2021213469 A AU2021213469 A AU 2021213469A AU 2021213469 B2 AU2021213469 B2 AU 2021213469B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
angiolipoma
acid
weight
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021213469A
Other languages
English (en)
Other versions
AU2021213469A1 (en
Inventor
Eran Blaugrund
Alon BLOOMENFELD
Racheli GUETA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raziel Therapeutics Ltd
Original Assignee
Raziel Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raziel Therapeutics Ltd filed Critical Raziel Therapeutics Ltd
Publication of AU2021213469A1 publication Critical patent/AU2021213469A1/en
Application granted granted Critical
Publication of AU2021213469B2 publication Critical patent/AU2021213469B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Prostheses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
AU2021213469A 2020-01-28 2021-01-27 Compositions for the treatment of angiolipoma Active AU2021213469B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062966577P 2020-01-28 2020-01-28
US62/966,577 2020-01-28
PCT/IB2021/000035 WO2021152390A1 (en) 2020-01-28 2021-01-27 Compositions for the treatment of angiolipoma

Publications (2)

Publication Number Publication Date
AU2021213469A1 AU2021213469A1 (en) 2022-08-25
AU2021213469B2 true AU2021213469B2 (en) 2026-06-04

Family

ID=77078612

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021213469A Active AU2021213469B2 (en) 2020-01-28 2021-01-27 Compositions for the treatment of angiolipoma

Country Status (7)

Country Link
US (1) US20230089484A1 (cg-RX-API-DMAC10.html)
EP (1) EP4096653A4 (cg-RX-API-DMAC10.html)
JP (1) JP7850665B2 (cg-RX-API-DMAC10.html)
CN (1) CN115335047B (cg-RX-API-DMAC10.html)
AU (1) AU2021213469B2 (cg-RX-API-DMAC10.html)
IL (1) IL295014B1 (cg-RX-API-DMAC10.html)
WO (1) WO2021152390A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203468A1 (en) 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
EP4031130A4 (en) * 2019-09-15 2023-10-11 Raziel Therapeutics Ltd. COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS
US20240335424A1 (en) * 2021-07-28 2024-10-10 Raziel Therapeutics Ltd. Compositions and methods for treating lipoma pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013072915A1 (en) * 2011-11-15 2013-05-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Tricyclic compounds, compositions comprising them and uses thereof
WO2016020919A1 (en) * 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof
WO2016203468A1 (en) * 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058139A1 (en) * 2009-11-12 2011-05-19 Selvita Sp. Z O. O. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
RU2020111934A (ru) * 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
AU2014340351B2 (en) * 2013-10-21 2020-01-30 Alevere Medical Corporation Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013072915A1 (en) * 2011-11-15 2013-05-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Tricyclic compounds, compositions comprising them and uses thereof
WO2016020919A1 (en) * 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof
WO2016203468A1 (en) * 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Raziel Therapeutics Ltd., "RZL-012 for Dercum's Disease Lipomas." NCT04229030, version 1, 13 January 2020. URL: https://clinicaltrials.gov/study/NCT04229030?term=NCT04229030&rank=1&tab=history&a=1#version-content-panel *

Also Published As

Publication number Publication date
CN115335047B (zh) 2025-09-19
CN115335047A (zh) 2022-11-11
JP7850665B2 (ja) 2026-04-23
IL295014A (en) 2022-09-01
IL295014B1 (en) 2026-05-01
EP4096653A1 (en) 2022-12-07
AU2021213469A1 (en) 2022-08-25
WO2021152390A1 (en) 2021-08-05
EP4096653A4 (en) 2024-02-28
US20230089484A1 (en) 2023-03-23
JP2023510865A (ja) 2023-03-15